🚀 VC round data is live in beta, check it out!
Amplia Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Amplia Therapeutics and similar public comparables like OnKure Therapeutics, Atossa Therapeutics, Aligos Therapeutics, Molecure and more.
Amplia Therapeutics Overview
About Amplia Therapeutics
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways: VEGFR3 and FLT3.
Founded
2013
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$23M
Amplia Therapeutics Financials
Amplia Therapeutics reported last 12-month revenue of — and negative EBITDA of ($7M).
In the same LTM period, Amplia Therapeutics generated — in gross profit, ($7M) in EBITDA losses, and had net loss of ($7M).
Revenue (LTM)
Amplia Therapeutics P&L
In the most recent fiscal year, Amplia Therapeutics reported revenue of — and net income of —.
Amplia Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($7M) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Amplia Therapeutics Stock Performance
Amplia Therapeutics has current market cap of $43M, and enterprise value of $23M.
Market Cap Evolution
Amplia Therapeutics' stock price is $0.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23M | $43M | -0.8% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAmplia Therapeutics Valuation Multiples
Amplia Therapeutics trades at (3.3x) EV/EBITDA.
EV / Revenue (LTM)
Amplia Therapeutics Financial Valuation Multiples
As of March 28, 2026, Amplia Therapeutics has market cap of $43M and EV of $23M.
Equity research analysts estimate Amplia Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Amplia Therapeutics has a P/E ratio of (6.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV (current) | $23M | XXX | $23M | XXX | XXX | XXX |
| EV/EBITDA | (3.3x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (3.3x) | XXX | — | XXX | XXX | XXX |
| P/E | (6.1x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Amplia Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Amplia Therapeutics Margins & Growth Rates
Amplia Therapeutics' revenue in the last fiscal year grew by —.
Amplia Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 15% | XXX | 54% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Amplia Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OnKure Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Atossa Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aligos Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Molecure | XXX | XXX | XXX | XXX | XXX | XXX |
| Corline Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amplia Therapeutics M&A Activity
Amplia Therapeutics acquired XXX companies to date.
Last acquisition by Amplia Therapeutics was on XXXXXXXX, XXXXX. Amplia Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Amplia Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAmplia Therapeutics Investment Activity
Amplia Therapeutics invested in XXX companies to date.
Amplia Therapeutics made its latest investment on XXXXXXXX, XXXXX. Amplia Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Amplia Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Amplia Therapeutics
| When was Amplia Therapeutics founded? | Amplia Therapeutics was founded in 2013. |
| Where is Amplia Therapeutics headquartered? | Amplia Therapeutics is headquartered in Australia. |
| Is Amplia Therapeutics publicly listed? | Yes, Amplia Therapeutics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Amplia Therapeutics? | Amplia Therapeutics trades under ATX ticker. |
| When did Amplia Therapeutics go public? | Amplia Therapeutics went public in 2013. |
| Who are competitors of Amplia Therapeutics? | Amplia Therapeutics main competitors are OnKure Therapeutics, Atossa Therapeutics, Aligos Therapeutics, Molecure. |
| What is the current market cap of Amplia Therapeutics? | Amplia Therapeutics' current market cap is $43M. |
| Is Amplia Therapeutics profitable? | No, Amplia Therapeutics is not profitable. |
| What is the current EBITDA of Amplia Therapeutics? | Amplia Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Amplia Therapeutics? | Current EBITDA multiple of Amplia Therapeutics is (3.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.